[1] Grigsby PW,Winter K,Wasserman TH,et al.Irradiation with or without misonidazole for patients with stages ⅢB and IV A carcinoma of the cervix:final results of RTOG 80-05[J].Int J Radiat Oncol Biol Phys,1999,44(3):513-517.
[2] Siim BG,Menke DR,Dorie MJ,et al.Tirapazamine-induced cytotoxicity and DN A damage in transplanted tumors:relationship to tumor hypoxia[J].Cancer Res,1997,57:2922-2928.
[3] Brown JM.The hypoxtc cell:a target for selective cancer therapy-eighteenth Bruce F.Cain Memorial Award lecture[J].Cancer Res,1999,59:5863-5870.
[4] Shulman LN,Busmell L,Riese N,et al.Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors[J].Int J Radiat Oncol Biol Phys,1999,44(2):349-353.
[5] Lee D-J,Trotti A,Spencer S,et al.Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas:a Phase Ⅱ study[J].Int J Radiat Oncol Biol Phys,1998,42:811-815.
[6] Mitchell JB,Cook JA,Krishna MC,et al.Radlation sensitisation by nitric oxide releasing agents[J].Br J Cancer,1996,74(Suppl.27):S 181-S 184.
[7] Griffin RJ,Wakepeace CM,Hur W J,et al.Radiosensitization of hypoxic tumor cells in vitro by nitric oxide[J].Int J Radiat Oncol Biol Phys,1996,36:377-383.
[8] Verovski VN,Van den Berge DL,Soete GA,et al.Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside[J].Br J Cancer,1996,74:1734-1742.
[9] Janssens M Y,Verovski VN,Van den Berge DL,et al.Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation[J].Br J Cancer,1999,79:1086-1089.
[10] Jordan BF,Misson P,Demeure R,et al.Changes in tumor oxygenation/perfusion induced by the NO donor,isosorbide dinitrate,in comparison with carbogen:monitoring by EPR and MRI[J].Int J Radiat Oncol Biol Phys,2000,48(2):565-570.
[11] Khandelwal SR,Kavanagh BD,Lin P-S,et al.RSR 13,an allosteric effector of haemoglobin,and carbogen radiosensitize FSaⅡ and SCCVⅡ tumours in C3H mice[J].Br J Cancer,1999,79:814-820.
[12] Teicher BA,Ara G,Emi Y,et al.RSR13:effects on tumor oxygenation and response to therapy[J].Drug Dev Res,1996,38:1-11.
[13] Kavanagh BD,Khandelwal SR,Schmidt-Ullrich RK,et al.A phase IB study to evaluate repeated daily intravenous doses of RSR13 administered to cancer patients receiving concurrent radiation therapy[J].Int J Radiat Oncol Biol Phys,1997,39:330S.
[14] Young SW,Qine F,Harriman A,et al.Gadolinium(Ⅲ) texaphyrin:a tumor selective radlation sensitizer that is detectable by MRI[J].Proc Natl Acad Sci USA,1996,93:6810-6615.
[15] Miller RA,Woodburn K,Fan Q,et al.In vivo animal studies with Gadolinium(Ⅲ) texaphyrin as a radiation enhancer[J].Int J Radiat Oncol Biol Phys,1999,45(4):981-989.
[16] Sessler JL,Miller RA.Texaphyrins:new drugs with diverse clinical applications in radiation and photodynamic therapy[J].Biochem Pharmacol,2000,59(7):733-739.
[17] Bernhard EJ,Mitchell JB,Deen D,et al.Re-evalnating gadolinium(Ⅲ)texaphyrin as a radiosensitizing agent[J].Cancer Res,2000,60(1),86-91.
[18] Lawrence TS,Eisbruch A,McGinn CJ,et al.Radiosensitization by gemcitabine[J].Oncology,1999,13(10 suppl.5):55-60.
[19] Ezekiel MP,Robert F,Meredith RF,et al.Phase I study of anti-epidermal growth factor receptor antibody c225 in combination with irradiation inpatients with advanced squamous cell carcinoma of the head and neck[J].Proc Am Soc Clin Oncol,1998,17:395a.
[20] Wouters BG,Brown JM.Cells at intermediate oxygen levels can be more important than the "hypoxicfraction" in determining tumor response to fractionated radiotherapy[J].Radiat Res,1997,147:541-550.